DexCom (DXCM) – Research Analysts’ Weekly Ratings Updates

DexCom (NASDAQ: DXCM) recently received a number of ratings updates from brokerages and research firms:

• 5/18/2026 – DexCom was given a new $82.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 5/18/2026 – DexCom had its “underweight” rating reaffirmed by Barclays PLC. They now have a $64.00 price target on the stock, down from $67.00.
• 5/18/2026 – DexCom had its price target lowered by Bank of America Corporation from $100.00 to $80.00. They now have a “buy” rating on the stock.
• 5/15/2026 – DexCom was upgraded by William Blair to “strong-buy”.
• 5/11/2026 – DexCom is now covered by Benchmark Co.. They set a “buy” rating and a $77.00 price target on the stock.
• 5/11/2026 – DexCom was upgraded by Benchmark Co. to “strong-buy”.
• 5/10/2026 – DexCom was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 5/4/2026 – DexCom had its “buy” rating reaffirmed by Citigroup Inc.. They now have a $79.00 price target on the stock, down from $84.00.
• 5/2/2026 – DexCom was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/1/2026 – DexCom was given a new $77.00 price target by Sanford C. Bernstein.
• 5/1/2026 – DexCom was given a new $80.00 price target by Robert W. Baird.
• 5/1/2026 – DexCom was given a new $75.00 price target by Mizuho.
• 5/1/2026 – DexCom was given a new $81.00 price target by Raymond James Financial, Inc..
• 5/1/2026 – DexCom was given a new $100.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 5/1/2026 – DexCom was given a new $67.00 price target by Barclays PLC. They now have an “underweight” rating on the stock.
• 5/1/2026 – DexCom had its price target lowered by TD Cowen from $84.00 to $75.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the transaction, the executive vice president directly owned 111,204 shares of the company’s stock, valued at $7,010,300.16. This represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the transaction, the director directly owned 25,007 shares in the company, valued at approximately $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 6,112 shares of company stock worth $379,990. 0.28% of the stock is owned by insiders.

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.